BioNTech develops a specific vaccine for children from 5 to 11 years old

File photograph.
File photograph. / SUR
  • Production will start shortly and the laboratory is preparing another for babies and infants from 6 months to 5 years

The German laboratory BioNTech, creator of the first coronavirus vaccine together with the American pharmaceutical company Pfizer, has developed a specific formula to vaccinate children aged between 5 and 11 years old.

The company has announced "we are starting production," in a statement published in Der Spiegel this Friday, 10 September, by Özlem Türeci, co-founder of BioNTech and one of the scientists involved in the development of its vaccines.

"In the coming weeks we will present to the authorities around the world the results of our study with children aged 5 to 11 years and we will request their authorisation, as well as here in Europe", added the expert, who said that "the vaccine is the same as that of adults, but not so highly dosed and the amount to be administered is also less.”

The results and conclusions of the study have already been drawn up and the only thing left to do is to finalise their presentation to the regulatory authorities.

"Everything looks very good, everything is going according to plan," says Ugur Sahin, Özlem Türeci's husband and co-founder of the German laboratory, in the same interview.

He added that by the end of the year they also hope to have the results of studies carried out with children and babies from six months to five years of age.

The two German scientists, of Turkish origin, also call on the authorities to try to convince those reluctant to be vaccinated to be jabbed in the coming weeks. "Society has about 60 days left to avoid a severe winter," warns Sahin, who stresses that "we must do everything possible to vaccinate the largest number of people in those two months."